文献速递银屑病与炎症性皮肤病

外用芦可替尼:白癜风治疗新选择

Topical ruxolitinib: A new treatment for vitiligo.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-05-15

本文综述外用芦可替尼(选择性JAK1/2抑制剂)治疗白癜风的疗效与安全性证据。1.5%芦可替尼乳膏已基于III期TRuE-V1和TRuE-V2试验数据在美国获批用于年龄>12岁的非节段性白癜风患者,现有结果提示其是治疗白癜风的有效手段。

要点

  • 1.5%芦可替尼乳膏在美国获批用于年龄>12岁的非节段性白癜风患者。
  • 获批依据为III期TRuE-V1和TRuE-V2临床试验数据。
  • 现有结果提示1.5%芦可替尼乳膏是治疗白癜风的有效手段。

核心结论

  • 现有结果提示1.5%芦可替尼乳膏是治疗白癜风的有效手段。

研究设计与样本

  • 本文为综述,旨在描述外用芦可替尼治疗白癜风的疗效与安全性证据,并讨论其在低龄儿童、妊娠或哺乳期女性中的使用及治疗时长与持久性问题。

主要发现

  • 1.5%芦可替尼乳膏在美国获批用于年龄>12岁的非节段性白癜风患者,依据为III期TRuE-V1和TRuE-V2临床试验数据。

关键数值与推荐

  • 1.5%芦可替尼乳膏在美国获批用于年龄>12岁的非节段性白癜风患者。
  • 获批依据为III期TRuE-V1和TRuE-V2临床试验数据。

临床怎么用

  • 白癜风为局限于皮肤的慢性疾病,外用治疗而非系统治疗可能更可取,尤其对局部皮损患者,以避免系统治疗的长期副作用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vitiligo is a chronic autoimmune skin disorder whose diagnosis is often psychologically upsetting. The efficacy of the available therapies, including topical corticosteroids and topical calcineurin inhibitors, has historically been limited and the management of vitiligo is still challenging. As vitiligo is a chronic disease limited to the skin, topical rather than systemic therapies may be preferable (especially among patients with localised lesions) to avoid the long-term side-effects of the latter. A topical formulation of ruxolitinib, a selective JAK1/2 inhibitor, has recently been approved in the United States for the treatment of non-segmental vitiligo in patients aged >12 years based on data from the phase III TRuE-V1 and TRuE-V2 clinical trials. The aim of this review is to describe the current evidence concerning the efficacy and safety of topical ruxolitinib in the treatment of vitiligo, and discuss issues regarding its use in younger children and pregnant or breastfeeding women, as well as the duration and durability of treatment. The promising results obtained so far suggest that 1.5% ruxolitinib cream is an effective means of treating vitiligo.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Tavoletti G, Avallone G, Conforti C, et al. Topical ruxolitinib: A new treatment for vitiligo. J Eur Acad Dermatol Venereol. 2023. PMID: 37147856. doi:10.1111/jdv.19162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。